Fatigue in Primary Biliary Cholangitis: Factors Associated With Severity and Persistence as Future Therapeutic Targets (RU SOMACROSS)

原发性胆汁性胆管炎的疲劳:与作为未来治疗目标的严重性和持久性相关的因素(RU SOMACROSS)

基本信息

项目摘要

Fatigue is a common symptom and the major ‘unmet need’ in the management of patients with primary biliary cholangitis (PBC). There are few prospective studies that address the development of PBC-associated fatigue over time and histologic grades. At the same time, few biological and psychosocial risk factors and mechanisms have been identified that could explain the development and maintenance of fatigue in PBC. In order to identify patients at risk for severe fatigue at an early stage, prospective studies that apply a comprehensive approach, synthesizing perspectives and integrating potential biomedical and psychological risk factors of fatigue are needed. It is the overall aim of our project to identify factors that determine the course and severity of fatigue as the main unmet clinical need in PBC, and to target these factors within deliverable interventions, in order to improve quality of life for our patients. In a cross-sectional part of our prospective twelve-month cohort study, we aim to simultaneously examine clinically relevant biomedical and psychosocial factors, and systematically assess and compare associations and interactions between these factors and fatigue in n = 240 patients with PBC (a patient group severely affected by fatigue) and n = 240 patients with PSC (a control cholestatic liver disease group much less affected by fatigue). In a prospective part, we will longitudinally monitor these variables to identify factors that determine the severity of fatigue over time. In order to complement our quantitative data by evidence other than self-report, we will embed an experimental study and qualitative interviews in a subsample of n = 48 patients with newly diagnosed PBC. Both approaches represent a valuable opportunity for an in-depth exploration of mechanisms of fatigue perception, development and maintenance. By applying a mixed method approach within a prospective design, we will gain innovative knowledge on the predictive role of biomedical and psychosocial risk factors for fatigue that are amenable to change. This will enhance our understanding of the aetiology of PBC-fatigue and enable the design of interventions to reduce fatigue. In terms of the overall aims of RU SOMACROSS, we will contribute to the development of a disease-overarching multivariable prediction model for persistent somatic symptoms, which will facilitate a common understanding of chronic symptoms across diseases and medical disciplines.
疲劳是原发性胆管炎(PBC)患者的常见症状和主要“未满足的需求”。很少有前瞻性研究,解决了PBC相关的疲劳随着时间的推移和组织学分级的发展。与此同时,很少有生物和心理社会的危险因素和机制已被确定,可以解释PBC疲劳的发展和维持。为了在早期阶段识别有严重疲劳风险的患者,需要采用综合方法,综合观点并整合疲劳的潜在生物医学和心理风险因素的前瞻性研究。我们项目的总体目标是确定确定疲劳的病程和严重程度的因素,作为PBC中主要未满足的临床需求,并在可交付的干预措施中针对这些因素,以提高患者的生活质量。在我们为期12个月的前瞻性队列研究的横断面部分,我们的目标是同时检查临床相关的生物医学和心理社会因素,并系统评估和比较这些因素与n = 240例PBC患者疲劳之间的关联和相互作用(受疲劳严重影响的患者组)和n = 240例PSC患者(受疲劳影响小得多的对照胆汁淤积性肝病组)。在前瞻性部分,我们将纵向监测这些变量,以确定随着时间的推移,疲劳的严重程度的因素。为了补充我们的定量数据的证据以外的自我报告,我们将嵌入一个实验研究和定性访谈的子样本n = 48例新诊断的PBC患者。这两种方法代表了一个宝贵的机会,深入探索疲劳的感知,发展和维护的机制。通过在前瞻性设计中应用混合方法,我们将获得关于生物医学和心理社会风险因素对疲劳的预测作用的创新知识。这将增强我们对PBC疲劳病因的理解,并使干预措施的设计能够减少疲劳。在RU SOMACROSS的总体目标方面,我们将致力于开发持续性躯体症状的疾病总体多变量预测模型,这将有助于跨疾病和医学学科对慢性症状的共同理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Professor Dr. Christoph Schramm其他文献

Professor Dr. Christoph Schramm的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Professor Dr. Christoph Schramm', 18)}}的其他基金

Coordination Funds
协调基金
  • 批准号:
    426581255
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
    Clinical Research Units
Molecular pathogenesis and signaling pathways: identification of therapeutic targets in primary sclerosing cholangitis (PSC)
分子发病机制和信号通路:原发性硬化性胆管炎 (PSC) 治疗靶点的鉴定
  • 批准号:
    417889840
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Regulatorische T-Zellen in der Therapie entzündlicher Lebererkrankungen
调节性T细胞在炎症性肝病治疗中的应用
  • 批准号:
    35346795
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Mechanismen der Asthmaresistenz durch regulatorische T-Zellen und TGFß1
通过调节性 T 细胞和 TGFα1 抵抗哮喘的机制
  • 批准号:
    5420981
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
    Research Grants
The role of androgens in autoimmune liver diseases
雄激素在自身免疫性肝病中的作用
  • 批准号:
    453861134
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
    Research Units

相似国自然基金

相似海外基金

New Therapy for the Treatment of Primary Biliary Cholangitis.
治疗原发性胆汁性胆管炎的新疗法。
  • 批准号:
    10697484
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Involvement and mechanism of endosomal regulatory molecule RIN3 in the development of primary biliary cholangitis
内体调节分子RIN3在原发性胆汁性胆管炎发生发展中的参与及机制
  • 批准号:
    23K19471
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Pathogenesis of refractory primary biliary cholangitis for UDCA and novel therapeutic strategies
UDCA难治性原发性胆汁性胆管炎的发病机制及新的治疗策略
  • 批准号:
    23K06460
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of the role of Receptor activator of nuclear factor kappa-B (RANK)/RANK ligand (RANKL) signals in the onset and progression of primary biliary cholangitis
阐明核因子 kappa-B 受体激活剂 (RANK)/RANK 配体 (RANKL) 信号在原发性胆汁性胆管炎的发病和进展中的作用
  • 批准号:
    23K15024
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the pathological mechanism of primary biliary cholangitis by antigen epitope analysis
抗原表位分析阐明原发性胆汁性胆管炎的病理机制
  • 批准号:
    22K15262
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Remogliflozin Etabonate Effect on Primary Biliary Cholangitis
瑞莫格列净依碳酸对原发性胆汁性胆管炎的影响
  • 批准号:
    10323592
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
PBC Predict: Prediction models and predictive biomarkers for primary biliary cholangitis
PBC 预测:原发性胆汁性胆管炎的预测模型和预测生物标志物
  • 批准号:
    MR/T023848/1
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Pathogenesis of Primary Biliary Cholangitis
原发性胆汁性胆管炎的发病机制
  • 批准号:
    10320394
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Mechanistically based therapeutic strategies in murine primary biliary cholangitis
小鼠原发性胆汁性胆管炎的机制治疗策略
  • 批准号:
    10337052
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Mechanistically based therapeutic strategies in murine primary biliary cholangitis
小鼠原发性胆汁性胆管炎的机制治疗策略
  • 批准号:
    10553286
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了